On completion of the article, the reader should be able to:
- Define the benefits of prophylactic fluconazole administration.
- Identify the population benefiting from the use of fluconazole.
- Use this information in a clinical setting.
Dr. Kollef has disclosed that was previously the recipient of direct grant/research funding from Intrabiotics and is currently the recipient of direct grant/research funding from Pfizer, Merck Bard, and Elan. Dr. Kollef has also disclosed that he is on the speakers bureau of Pfizer and Merck. All of the remaining authors have disclosed that they have no financial relationships with or interests in any commercial companies pertaining to this educational activity.
Wolters Kluwer Health has identified and resolved all faculty conflicts of interest regarding this educational activity.
Visit the Critical Care Medicine Web site (www.ccmjournal.org) for information on obtaining continuing medical education credit.
To evaluate the impact of fluconazole prophylaxis on the incidence of fungal infections and on mortality among critically ill surgical patients.
Meta-analysis of randomized, placebo-controlled trials of fluconazole prophylaxis.
Subjects participating in the clinical trials in this area.
We identified four randomized studies comparing fluconazole to placebo for prevention of fungal infections in the surgical intensive care unit (SICU). The studies enrolled 626 patients and used differing dosing regimens of fluconazole. All trials were double-blind and two were multicenter studies. Fluconazole administration significantly reduced the incidence of fungal infections (pooled odds ratio, 0.44; 95% confidence interval, 0.27–0.72; p < .001). However, fluconazole prophylaxis was not associated with a survival advantage (pooled OR for mortality, 0.87; 95% confidence interval, 0.59–1.28; p = NS). Fluconazole did not statistically alter the rate of candidemia, as this was low across the studies and developed in only 2.2% of all participants. Performing a sensitivity analysis and including two additional studies that indirectly examined fluconazole prophylaxis in the critically ill did not change our observations. Data from the reports reviewed were insufficient to allow comment on the impact of fluconazole prophylaxis on resource utilization, the distribution of nonalbicans species of Candida, and the emergence of antifungal resistance. Generally, fluconazole appeared to be safe for SICU patients.
Prophylactic fluconazole administration for prevention of mycoses in SICU patients appears to successfully decrease the rate of these infections, but this strategy does not improve survival. The absence of a survival advantage may reflect the few studies in this area and the possibility that this issue has not been adequately studied. Because of the potential for both resistance and emergence of nonalbicans isolates, clinicians must consider these issues when evaluating fluconazole prophylaxis in the SICU. Future trials should focus on more precisely identifying patients at high risk for fungal infections and on determining if broader use of fluconazole alters the distribution of candidal species seen in the SICU and impacts measures of resource utilization such as length of stay and duration of mechanical ventilation.
Associate Chief, Pulmonary and Critical Care, Associate Professor of Medicine, Washington Hospital Center, Medstar, Potomac, MD (AFS); Critical Care Fellow (KC), Assistant Chief, Critical Care Medicine Service (WLJ), Resident Physician, Internal Medicine (PEW), Walter Reed Army Medical Center, Washington, DC; Professor of Medicine, Washington University School of Medicine, St. Louis, MO (MHK).
The opinions expressed herein are not to be construed as official or as reflecting the policies of either the Department of the Army or Department of Defense.
Address all correspondence to Dr. Andrew Shorr Pulmonary and Critical Care Medicine Washing-ton Hospital Center Washington, DC 20010 Phone: 202–877–2998 Fax: 202–782–9032 Email: email@example.com